According to an article published in Health Medicine Network:
Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer complications of the disease, according to an analysis of University of Pittsburgh Medical Center patients who received the medication compared to similar patients who did not.
“The fact that we found bamlanivimab to be this effective in keeping our patients with COVID-19 out of the hospital bodes very well for the future use of the currently available monoclonal therapies, something we are studying now,” said lead author Ryan Bariola, M.D., associate professor in Pitt’s Division of Infectious Diseases and Director of the UPMC Community Hospital Antimicrobial Stewardship Efforts (CHASE) Program. “If given early to high-risk patients, this treatment works to prevent COVID-19-related complications. We look forward to research with next-generation monoclonal antibodies and hope to continue to find safe and effective treatments for our patients.”– “COVID-19 monoclonal antibodies reduce risk of hospitalization and death“
We are seeing the light at the end of the tunnel, and it is comforting to know that researchers are still researching right? Tomorrow may shed new light on something we never thought possible and in the wake of COVID-19, that is great news!
Stay well and stay tuned!